This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

André Cartier, MD; Jean-Luc Malo, MD; Denyse Gautrin, PhD
Hôpital du Sacré-Coeur Montreal, Quebec

Louis-Philippe Boulet, MD
Hôpital Laval Quebec City

Helénè Boisjoly, MD, MPH
Hôpital Maisonneuve-Rosemont Montreal, Quebec

JAMA. 1997;277(24):1929-1930.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Garbe and colleagues¹ incriminate highdose inhaled corticosteroids in the increased risk of ocular hypertension and open-angle glaucoma. However, several substantial criticisms can be made regarding this study.

The distinction between ocular hypertension and glaucoma, the case definition, is not of minor importance as claimed by the authors. In the report by Garbe et al, 51% of cases did not receive any treatment for glaucoma, which is unusual. One would expect that these at-risk subjects would be followed up by their ophthalmologists within 4 to 6 months; this could be verified by the authors.

In this older population, COPD from cigarette smoking is probably more frequent than asthma per se; both conditions are often treated with inhaled corticosteroids, although the indication for steroids in COPD is controversial. Cigarette smoking is a known risk factor for development of cataract² and cardiovascular diseases.³ On one hand, topical glucocorticoids usually . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?